You are now leaving Alpha1Health.com.

Baxter is not responsible for the privacy policy, the content or the accuracy of any web site accessed through a link on the Alpha1Health.com site. A link to other web sites does not constitute an endorsement by Baxter of the linked site, its products or services.

The browser window or tab for Alpha1Health.com will remain open underneath the new browser window or tab. To return to Alpha1Health.com at any time, close this tab or window.

Order AAT Augmentation

It’s easy to start your patients on GLASSIA or ARALAST NP. Just select the ordering method that’s most convenient.

Seven of the nation’s leading specialty pharmacies can dispense Baxter AAT Augmentation to your patients.*

Accredo Therapeutics

1-866-6-ALPHA1 (866-625-7421)
www.accredo.com

CuraScript SP

1-888-773-7376
www.curascript.com

BioRx

1-866-44BIORX
www.biorx.net

US Bioservices

1-888-518-7246
www.usbioservices.com

Caremark Inc.

1-800-552-8159
www.caremark.com

Walgreens, Infusion and Respiratory Services

1-888-782-8443
www.walgreens.com/pharmacy
/specialtypharmacy

Coram Healthcare

1-866-FOR-A1PI (866-367-2174)
www.coramhc.com/Services/Alpha1.aspx

*Aralast NP is available to new patients through Accredo Therapeutics, Caremark, Inc., and Coram Healthcare.

With home care, your patients will enjoy these benefits:

Comprehensive in-home care

  • Patients are cared for by a team of highly qualified, experienced pharmacists, nurses, and client representatives

Education and nursing support

  • Professional resources for all therapy options, from self infusion to nurse administered
  • Convenience within the patient's home or workplace

Advocacy programs

  • Case managers work with patients to advocate for access to benefits and to identify and secure appropriate reimbursment levels
  • Provide information on insurance issues and state programs

Nurse-to-physician information

  • Regular communication with physician ensures quality patient care

Nationwide service

  • Comprehensive service whenever patients need therapy

Hospital/Infusion Suites for Medicare Recipients

If you or your patients have questions about accessing therapy with GLASSIA or ARALAST NP, call 1-866-272-5278.

Order AAT Augmentation Online

To use Baxter's eServices Center website, you must be pre-registered. To register, click on the link below and follow the instructions. Your login ID and password will be required each time you use the site.

https://www.ecomm.baxter.com/css/welcome.do

Hours of Operation for the eServices Center

7:00 am – 6:00 pm (Central Time)
Monday through Friday

Please note that when you use the eServices Center you are on a different website. The levels of security for submitted information may be different between the eServices site and alpha1health.com.

These links are provided for your convenience. However, they lead to external websites not created, managed, or maintained by Baxter. Baxter is not responsible for, and does not necessarily endorse, the opinions or products represented on these external pages.

GLASSIA [Alpha1-Proteinase Inhibitor (Human)]

GLASSIA is indicated for chronic augmentation and maintenance therapy in individuals with emphysema due to congenital deficiency of alpha1-proteinase inhibitor (Alpha1-PI), also known as alpha1-antitrypsin (AAT) deficiency.

  • The effect of augmentation therapy with GLASSIA or any Alpha1-PI product on pulmonary exacerbations and on the progression of emphysema in Alpha1-PI deficiency has not been demonstrated in randomized, controlled clinical trials.
  • Clinical data demonstrating the long term effects of chronic augmentation and maintenance therapy of individuals with GLASSIA are not available.
  • GLASSIA is not indicated as therapy for lung disease in patients in whom severe Alpha1-PI deficiency has not been established.

Detailed Important Risk Information for GLASSIA

  • GLASSIA is contraindicated in IgA deficient patients with antibodies against IgA. GLASSIA is contraindicated in individuals with a history of severe immediate hypersensitivity reactions, including anaphylaxis, to Alpha1-PI products.
  • GLASSIA is made from human plasma. It may carry a risk of transmitting infectious agents, such as viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
  • Administer GLASSIA at room temperature at a rate not greater than 0.04 mL/kg body weight per minute. If anaphylactic or severe anaphylactoid reactions occur, discontinue the infusion immediately.
  • Administer GLASSIA within 3 hours of entering the vials.
  • Safety and effectiveness in patients over 65 years of age have not been established.
  • Two serious adverse reactions observed on two separate occasions during clinical studies with GLASSIA were cholangitis and exacerbation of chronic obstructive pulmonary disease (COPD).
  • The most common product-related adverse reactions in clinical studies were headache and dizziness.

Please see GLASSIA Full Prescribing Information for full prescribing details.

ARALAST NP [Alpha1-Proteinase Inhibitor (Human)]

ARALAST NP is indicated for chronic augmentation therapy in patients having congenital deficiency of A1-PI with clinically evident emphysema.

  • The effect of augmentation therapy with ARALAST NP on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials.
  • Clinical data demonstrating the long-term effects of chronic augmentation or replacement therapy of individuals with ARALAST NP or ARALAST are not available.
  • ARALAST NP is not indicated as therapy for lung disease patients in whom congenital A1-PI deficiency has not been established.

Detailed Important Risk Information for ARALAST NP

  • ARALAST NP is contraindicated in IgA deficient patients with antibodies against IgA, due to the risk of severe hypersensitivity.
  • ARALAST NP is derived from pooled human plasma. It may carry a risk of transmitting infectious agents, e.g., viruses and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
  • The recommended rate of administration (≤0.08 mL/kg/min) should be closely followed and vital signs monitored continuously. If anaphylactic or severe anaphylactoid reactions occur, the infusion should be discontinued immediately.
  • Safety and effectiveness in patients over age 65 years of age have not been established.
  • ARALAST NP should be administered at room temperature within three (3) hours after reconstitution and should be administered alone, without mixing with other agents or diluting solutions.
  • The safety of ARALAST NP was evaluated with ARALAST in a crossover clinical PK comparability study. The most common adverse events deemed related to ARALAST NP included headache and musculoskeletal discomfort. No serious adverse reactions or deaths were reported in the study. In the ARALAST pivotal study, the most common adverse events were headache and somnolence.

Please see ARALAST NP Full Prescribing Information for full prescribing details.